Term ended May 24, 2026 · Medium confidence
20-year base term ended Nov 18, 2023
Why Medium: A parent in the chain could not be resolved.
Held by Glaxo Group Limited
Filed Mar 26, 2010 as application 12/732,519 · Granted Mar 11, 2014
Base term plus 918 days of patent term adjustment (USPTO delay)
Today
Term ended May 24, 2026
2003
2026
Clock starts
Nov 18, 2003
Nov 18, 2003
Term ended
May 24, 2026
May 24, 2026
Granted
Mar 11, 2014
Mar 11, 2014
base term
patent term adjustment
after the term ends
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
918
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 918 days past its 20-year base term on prosecution delay. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 18, 2003, when application PCT/EP2003/013074, the earliest non-provisional in its chain, was filed (this one was filed Mar 26, 2010); a parent in its chain could not be resolved (the next row) | Nov 18, 2023 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +918 days, USPTO patent term adjustment record | May 24, 2026 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | May 24, 2026 | Medium confidence |
This family
| US 7,713,518 | In force Nov 2026 | Nov 2026 |
| US 8,668,928 | this patent May 2026 | May 2026 |
2 of 3 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 14, 2015 Reel 35637, frame 919 | Rand, Paul Kenneth | Glaxo Group Limited | Assignment of Assignor's Interest |
| Apr 16, 2025 Reel 71044, frame 904 | Glaxo Group Limited | Glaxo Group Limited | Change of Address |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
The 918 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.